Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression

Author(s)

Joaquim, Helena P. G. ^{[1, 2]} ; Talib, Leda L. ^{[1, 2]} ; Forlenza, Orestes V. ^{[1, 2]} ; Diniz, Breno S. ^{[3, 1, 2]} ; Gattaz, Wagner F. ^{[1, 2]}

Affiliation

^[1] Univ Sao Paulo, Fac Med, Dept Psychiat, Lab Neurosci LIM 27, BR-05403010 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Inst Psychiat, Lab Neurosci LIM 27, BR-05403010 Sao Paulo - Brazil

^[3] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA - USA

• Document type: Journal article
• Source: JOURNAL OF PSYCHIATRIC RESEARCH; v. 46, n. 8, p. 1053-1058, AUG 2012.
• Web of Science Citations: 12

Abstract

Background: Abnormal regulation of glycogen synthase kinase 3-beta (GSK3B) activity has been implicated in the pathophysiology of mood disorders. Many pharmacological agents, including antidepressants, can modulate GSK3B. The aim of the present study was to investigate the effect of short-and long-term sertraline treatment on the expression and phosphorylation of GSK3B in platelets of patients with late-life major depression. Methods: Thirty-nine unmedicated elderly adults with major depressive disorder (MOD) were initially included in this study. The comparison group comprised 18 age-matched, healthy individuals. The expression of total and Ser-9 phosphorylated GSK3B (pGSK3B) was determined by Enzyme Immunometric Assay (EIA) in platelets of patients and controls at baseline, and after 3 and 12 months of sertraline treatments for patients only. During this period, patients were continuously treated with therapeutic doses of sertraline. GSK3B activity was indirectly estimated by calculating the proportion of inactive (phosphorylated) forms (pGSK3B) in relation to the total expression of the enzyme (i.e.. GSK3B ratio). Results: Depressed patients had significantly higher levels of pGSK3B as compared to controls (p < 0.001). Within the MDD group, after 3 months of sertraline treatment no significant changes were observed in GSK3B expression and phosphorylation state, as compared to baseline levels. However, after 12 months of treatment we found a significant increase in the expression of total GSK3B (p = 0.05), in the absence of any significant changes in pGSK3B (p = 0.12), leading to a significant reduction in GSK3B ratio (p = 0.001). Conclusions: Our findings indicate that GSK3B expression was upregulated by the continuous treatment with sertraline, along with an increment in the proportion of active forms of the enzyme. This is compatible with an increase in overall GSK3B activity, which may have been induced by the long-term treatment of late-life depression with sertraline. (C) 2012 Elsevier Ltd. All rights reserved. (AU)

• FAPESP's process: 05/56464-9 - Neuroscience Imaging Center at University of São Paulo Medical School
• Grantee: Giovanni Guido Cerri
• Support Opportunities: Inter-institutional Cooperation in Support of Brain Research (CINAPCE) - Thematic Grants